Get started
Author

Iolanda Capone

Observed names: Capone, Iolanda, I. Capone
ORCID: 0000-0002-6572-614X
Observed ORCID: 0000-0002-6572-614X
OpenAlex ID: A5088756261
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
2022 · Federica Morano, Alessandra Raimondi, et al. · Journal of Clinical Oncology · 133
PDF
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift
2017 · Alessandra Fabbri, Mara Cossa, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 43
ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series
2022 · Margherita Ambrosini, Marzia Del Re, et al. · JCO Precision Oncology · 33
PDF
Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma
2017 · Angelica Sonzogni, Fabrizio Bianchi, et al. · The Journal of Pathology Clinical Research · 32
PDF
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care
2023 · Andrea Vingiani, Luca Agnelli, et al. · JCO Precision Oncology · 26
PDF
LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress–Based Treatments
2021 · Cristina Borzi, Monica Ganzinelli, et al. · Journal of Thoracic Oncology · 24
PDF
Molecular profiling of pediatric and young adult colorectal cancer reveals a distinct genomic landscapes and potential therapeutic avenues
2024 · A. Busico, P. Gasparini, et al. · Scientific Reports · 23
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
2021 · Roberto Moretto, Daniele Rossini, et al. · Clinical Colorectal Cancer · 21
Identification of potentially druggable molecular alterations in skin adnexal malignancies
2019 · Stefano Cavalieri, Adele Busico, et al. · The Journal of Dermatology · 17
383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)
2021 · F. Pietrantonio, F. Morano, et al. · Annals of Oncology · 16
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma
2019 · Antonino Belfiore, Adele Busico, et al. · International Journal of Molecular Sciences · 13
PDF
Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study
2025 · Valentina De Micheli, Luca Agnelli, et al. · BMJ Open · 11
Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice
2023 · Andrea Vingiani, Daniele Lorenzini, et al. · Cancer Biomarkers · 11
PDF
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
2022 · Iolanda Capone, Fabio Bozzi, et al. · Exploration of Targeted Anti-tumor Therapy · 11
PDF
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
2024 · Vincenzo Nasca, Natalie Prinzi, et al. · European Journal of Cancer · 10
PDF
Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer
2025 · Elena Conca, Daniele Lorenzini, et al. · Frontiers in Oncology · 8
PDF
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations
2025 · Federico Nichetti, Marta Brambilla, et al. · JCO Precision Oncology · 8
A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei
2023 · Shigeki Kusamura, Adele Busico, et al. · Biomedicines · 8
PDF
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
2024 · Marco Maria Germani, Guglielmo Vetere, et al. · Frontiers in Oncology · 7
A rare biclonal Hairy Cell Leukemia disclosed by an integrated diagnostic approach: A case report
2020 · Laura Vittoria, Fabio Bozzi, et al. · Cytometry Part B Clinical Cytometry · 7
PDF
Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.
2025 · Chiara Cremolini, Paolo Ciracì, et al. · Journal of Clinical Oncology · 6
PDF
Clinical evaluation of the role of miRNA 371 in small testicular masses. Results of the “S1STeM 371” Trial
2025 · Sebastiano Nazzani, Adele Busico, et al. · European Journal of Cancer · 6
Detecting gene copy number alterations by Oncomine Comprehensive genomic profiling in a comparative study on FFPE tumor samples
2025 · Fabio Bozzi, Elena Conca, et al. · Scientific Reports · 6
PDF
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
2022 · Jacopo Azzollini, Andrea Vingiani, et al. · Frontiers in Oncology · 6
A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers
2026 · S. Alfieri, S. Rota, et al. · ESMO Open · 4
PDF
Works count: 49
Citation count: 509
H-index: 11
I10-index: 15
Year
Topic
Type